Health Henan News: According to information from the Oncology Department of the First Affiliated Hospital of Zhengzhou University, recently, Ms. Liu (pseudonym), a patient with diffuse large B-cell lymphoma, received CAR-T cell therapy(YESCARTA) in the First Affiliated Hospital of Zhengzhou University, and her symptoms were completely relieved. , was successfully discharged from the hospital, and the treatment Ms. Liu received was CAR-T treatment of 1.2 million yuan per injection. This treatment, and the first case of 1.2 million injections in China last year, belong to the same treatment method and drug, and both are the first CAR-T cell therapy in China. This is the first patient to receive this treatment in the First Affiliated Hospital of Zhengzhou University after YESCARTA injection was launched in China. The patient’s smooth discharge marks that Henan has reached a new level in anti-tumor therapy.
It is reported that Ms. Liu is in her 40s and was diagnosed with diffuse large B-cell lymphoma. FISH showed multiple copies of C-MYC and BCL-2 with chromosomal polysomy (atypical double-hit subtype). She applied R-CHOP program 2 successively. After 2 cycles, R-CHOP regimen + Chidamide for 2 cycles, and Modified R-GEMOX + Chidamide regimen for 2 cycles, the disease was still not completely relieved. In November 2021, CAR-T treatment with akirenzai injection was started, and the period of side effects occurred smoothly. The efficacy was evaluated as complete remission (CR) after 2 months of reinfusion in early February 2022. At present, the patient has been successfully discharged from the hospital and is recovering.